Skip to main content Accessibility help
×
Home

Should Vascular Surgery Patients Be Screened Preoperatively for Methicillin-Resistant Staphylococcus aureus?

  • Bruce Y. Lee (a1) (a2) (a3), Becky Y. Tsui (a1) (a2) (a3), Rachel R. Bailey (a1) (a2) (a3), Kenneth J. Smith (a1), Robert R. Muder (a4) (a5), G. Jonathan Lewis (a1) (a2) (a3) and Lee H. Harrison (a6) (a3)...

Abstract

Background.

Methicillin-resistant Staphylococcus aureus (MRSA) can cause severe infection in patients who are undergoing vascular surgical operations. Testing all vascular surgery patients preoperatively for MRSA and attempting to decolonize those who have positive results may be a strategy to prevent MRSA infection. The economic value of such a strategy has not yet been determined.

Methods.

We developed a decision-analytic computer simulation model to determine the economic value of using such a strategy before all vascular surgical procedures from the societal and third-party payer perspectives at different MRSA prevalence and decolonization success rates.

Results.

The model showed preoperative MRSA testing to be cost-effective (incremental cost-effectiveness ratio, <$50,000 per quality-adjusted life year) when the MRSA prevalence is ≥0.01 and the decolonization success rate is ≥0.25. In fact, this strategy was dominant (ie, less costly and more effective) at the following thresholds: MRSA prevalence ≥0.01 and decolonization success rate ≥0.5, and MRSA prevalence ≥0.025 and decolonization success rate ≥0.25.

Conclusion.

Testing and decolonizing patients for MRSA before vascular surgery may be a cost-effective strategy over a wide range of MRSA prevalence and decolonization success rates.

Copyright

Corresponding author

University of Pittsburgh, 200 Meyran Ave, Rm 217, Pittsburgh, PA 15213 (BYLl@pitt.edu)

References

Hide All
1.Naylor, AR, Hayes, PD, Darke, S. A prospective audit of complex wound and graft infection in Great Britain and Ireland: the emergence of MRSA. Eur J Vase Endovasc Surg 2001;21:289294.
2.Nasim, A, Thompson, MM, Naylor, AR, Bell, PR, London, NJ. The impact of MRSA on vascular surgery. Eur J Vase Endovasc Surg 2001;22:211214.
3.Chalmers, RT, Wolfe, JH, Cheshire, NJ, et al.Improved management of infrainguinal bypass graft infection with methicillin-resistant Staphylococcus aureus. Br J Surg 1999;86:14331436.
4.Grimble, SA, Magee, TR, Galland, RB. Methicillin-resistant Staphylococcus aureus in patients undergoing major amputation. Eur J Vase Endovasc Surg 2001;22:215218.
5.Taylor, MD, Napolitano, LM. Methicillin-resistant Staphylococcus aureus infections in vascular surgery: increasing prevalence. Surg Infect (Larchmt) 2004;5:180187.
6.Cowie, SE, Ma, I, Lee, SK, Smith, RM, Hsiang, YN. Nosocomial MRSA infection in vascular surgery patients: impact on patient outcome. Vase Endovascular Surg 2005;39:327334.
7.Nather, A, Bee, CS, Huak, CY, et al.Epidemiology of diabetic foot problems and predictive factors for limb loss. J Diabetes Complications 2008;22:7782.
8.Richards, T, Pittathankel, AA, Purseil, R, Magee, TR, Galland, RB. MRSA in lower limb amputation and the role of antibiotic prophylaxis. J Cardiovasc Surg (Torino) 2005;46:3741.
9.Murphy, GJ, Pararajasingam, R, Nasim, A, Dennis, MJ, Sayers, RD. Methicillin-resistant Staphylococcus aureus infection in vascular surgical patients. Ann R Coll Surg Engl 2001;83:158163.
10.Thompson, M. An audit demonstrating a reduction in MRSA infection in a specialised vascular unit resulting from a change in infection control protocol. Eur J Vase Endovasc Surg 2006;31:609615.
11.Morange-Saussier, V, Giraudeau, B, van der Mee, N, Lermusiaux, P, Quentin, R. Nasal carriage of methicillin-resistant Staphylococcus aureus in vascular surgery. Ann Vase Surg 2006;20:767772.
12.Bounthavong, M, Hsu, DI, Okamoto, MP. Cost-effectiveness analysis of linezolid vs vancomycin in treating methicillin-resistant Staphylococcus awreus-complicated skin and soft-tissue infections using a decision analytic model. Int J Clin Pract 2009;63:376386.
13.Levit, K (Thomson Reuters), Stranges, E (Thomson Reuters), Ryan, K (Thomson Reuters), Elixhauser, A (AHRQ). HCUP Facts and Figures, 2006: Statistics on Hospital-Based Care in the United States. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Available at: http://www.hcup-us.ahrq.gov/reports.jsp. Accessed October 6, 1984.
14.Shannon, RP, Patel, B, Cummins, D, Shannon, AH, Ganguli, G, Lu, Y. Economics of central line-associated bloodstream infections. Am J Med Qual 2006;21(Suppl 6):7S16S.
15.Sackett, DL, Torrance, GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978;31:697704.
16.Gold, MR, Franks, P, McCoy, KI, Fryback, DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778792.
17.Tengs, TO, Wallace, A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583637.
18.Selai, C, Rosser, R. Eliciting EuroQol descriptive data and utility scale values from inpatients: a feasibility study. Pharmacoeconomics 1995;8:147158.
19.Reyes, J, Hidalgo, M, Diaz, L, et al.Characterization of macrolide resistance in gram-positive cocci from Colombian hospitals: a countrywide surveillance. Int J Infect Dis 2007;11:329336.
20.Cerveira, JJ, Lai, BK, Padberg, FT Jr, Pappas, PJ, Hobson, RW 2nd. Methicillin-resistant Staphylococcus aureus infection does not adversely affect clinical outcome of lower extremity amputations. Ann Vase Surg 2003;17:8085.
21.Zack, J. Zeroing in on zero tolerance for central line-associated bacteremia. Am J Infect Control 2008;36:S176.e1-2.
22.Bell, C, Urbach, D, Ray, J, et al.Bias in published cost effectiveness studies: systematic review. BMJ 2006;332:699703.
23.Shiroiwa, T, Sung, YK, Fukuda, T, Lang, HC, Bae, SC, Tsutani, K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost-effectiveness?Health Econ 2009 [epub ahead of print].
24.Wilmoth, JR, Shkolnikov, V. Human mortality database. Available at: http://www.humanmortality.de. Accessed January 21, 2008.
25.Graves, N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004;10:561566.
26.Graves, N, Halton, K, Lairson, D. Economics and preventing hospital-acquired infection: broadening the perspective. Infect Control Hosp Epidemiol 2007;28:178184.
27.Braithwaite, RS, Meitzer, DO, King, JT Jr, Leslie, D, Roberts, MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349356.
28.Laupacis, A, Feeny, D, Detsky, AS, Tugwell, PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473481.
29.Ammerlaan, HS, Kluytmans, JA, Wertheim, HF, Nouwen, JL, Bonten, MJ. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009;48:922930.
30.Lautenbach, E, Nachamkin, I, Hu, B, et al.Surveillance cultures for detection of methicillin-resistant Staphylococcus aureus: diagnostic yield of anatomic sites and comparison of provider- and patient-collected samples. Infect Control Hosp Epidemiol 2009;30:380382.
31.Marshall, C, Spelman, D. Re: is throat screening necessary to detect methicillin-resistant Staphylococcus aureus colonization in patients upon admission to an intensive care unit? J Clin Microbiol 2007;45:3855.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed